Zoetis Receives Positive CVMP Opinion for Lenivia®, a Novel Therapy to Reduce Osteoarthritis Pain in Dogs Zoetis Inc., a global leader in animal health, today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA)…
Prilenia and Ferrer Highlight Compelling New Evidence of Pridopidine’s Disease-Modifying Potential in Huntington’s Disease at the 2025 HSG Congress Prilenia Therapeutics B.V. and Ferrer have jointly announced the presentation of five new scientific posters at the 2025 Huntington Study Group…
Johnson & Johnson Urges Shareholders to Reject Below-Market “Mini-Tender” Offer by Tutanota LLC Johnson & Johnson (NYSE: JNJ) has issued a formal statement warning its shareholders against an unsolicited “mini-tender” offer initiated by Tutanota LLC, a limited liability company based…
Vividion Publishes Groundbreaking Science Study on Covalent RAS-PI3Kα Inhibitors That Halt Tumor Growth Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company and wholly owned, independently operated subsidiary of Bayer AG, has announced the publication of a pivotal manuscript in Science…
Perceptive Imaging Appoints Doug Fulling as CEO to Lead Global Growth, Enhance Services, and Drive Innovation in Clinical Trial Imaging Perceptive Imaging (“Perceptive” or “the Company”), a global leader in clinical trial imaging services for the pharmaceutical and biotech industries,…
Thermo Fisher Scientific Launches Molecular Microscope Diagnostic System to Transform Lung Transplant Rejection Detection and Management Thermo Fisher Scientific Inc., the global leader in serving science, has unveiled an innovative laboratory-developed test (LDT) that aims to revolutionize the detection and…
Aphios Corporation Awarded NIH Grant to Advance Botanical Drug Zindol® for Cancer-Related Nausea and Vomiting Aphios Corporation, a pioneer in the development of advanced botanical pharmaceuticals and nutraceuticals, has received a Small Business Innovation Research (SBIR) Phase I grant from…
Kairos Pharma to Present Promising Phase 2 Prostate Cancer Data Highlighting Carotuximab’s Potential to Overcome Hormone Therapy Resistance at ESMO 2025 Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics that address treatment…
Bimiralisib Topical PI3K/mTOR Inhibitor Demonstrates Up to 92% Clearance and Excellent Tolerability in Phase 2 Actinic Keratosis Trial Torqur AG, a clinical-stage biopharmaceutical company and a subsidiary of the Swiss Rockets AG incubator, has announced highly encouraging results from its…
CareDx Unveils New IVDR-Certified Transplant Diagnostics and Advanced HLA Typing Technologies at ASHI 2025 CareDx, Inc. widely recognized as The Transplant Company™ — announced a major wave of product innovations and regulatory milestones during the American Society for Histocompatibility and…
Global Lymphoma Antibody Drug Conjugates Market 2030: Pipeline, Patents, Prices, Approved Sales, and Clinical Trial Insights Lymphoma Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030”, providing an in-depth analysis of the evolving landscape…
Alnylam Pharmaceuticals Reports HELIOS-B Phase 3 Findings: Vutrisiran Reduces Gastrointestinal Events in ATTR-CM Patients Alnylam Pharmaceuticals, Inc. , a global leader in RNA interference (RNAi) therapeutics, today unveiled new analyses from the HELIOS-B Phase 3 study evaluating AMVUTTRA® (vutrisiran). Vutrisiran…